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Cellular regulationPreeclampsia (PE) is a hypertensive disorder of pregnancy, in which marinobufagenin (MBG), a circulating
cardiotonic steroid, is increased. The Gadd45a stress sensor protein is an upstream modulator of the
pathophysiological changes observed in PE. However, the effects of MBG on Gadd45a stress signaling remain
unknown. We examined the expression of Gadd45a, the sFlt-1 receptor, and p38, as well as caspase 3 and
8 activities in placental samples from four groups of rats. These were: normal pregnant (NP, n=8); pregnant
rats which received weekly injections of desoxycorticosterone acetate and 0.9% saline as their drinking water
(PDS, n=9); normal pregnant rats injected with MBG (NPM, n=8); and PDS rats injected with resibufogenin
(RBG), an in vivo antagonist of MBG (PDSR, n=8). Utilizing human cytotrophoblast (CTB) cells, we examined
the effect of MBG on these stress signaling proteins in vitro. Placental Gadd45a expression, caspase 3 and
8 activities, sFlt-1 concentrations, and sFlt-1 receptor expression were signiﬁcantly higher in PDS and NPM
compared to NP and PDSR rats. Gadd45a protein was signiﬁcantly upregulated in the CTB cells whenMBGwas
present in concentrations ≥1 nM. Treatment with MBG (≥1 nM) also signiﬁcantly arrested cell cycle
progression and activated the expression of the Gadd45a-mediated stress signaling proteins. Inhibition of
Gadd45a through RNAi-mediation attenuated MBG-induced CTB cell stress signaling. In conclusion, MBG is
involved in the alteration in Gadd45a stress signaling both in vivo and in vitro and RBG prevents these changes
when administered in vivo.rosine kinase; Gadd45, growth
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Marinobufagenin (MBG) is an endogenous mammalian cardioton-
ic bufadienolide [1] that inhibits the membrane-bound sodium pump
Na+/K+-ATPase [2,3] and has vasoconstrictive properties [4]. MBG
secretion occurs in response to increased plasma volume, and
circulating levels of MBG have been reported to be increased in
patients with volume expansion-mediated hypertension and pre-
eclampsia (PE) and in experimental animal models of PE [5–8]. PE is a
syndromewhich occurs in 3–10% of pregnancies and is a leading cause
of maternal and fetal morbidity and mortality [9–11]. This syndromeis characterized by the de novo development of hypertension and
proteinuria after 20 weeks of gestation [9,12]. The precise etiology
(etiologies) of this syndrome remain(s) unknown.
In a rat model of PE in which excessive volume expansion was
induced [13], we have shown that the urinary excretion of MBG is
elevated prior to the development of hypertension and proteinuria.
These ﬁndings implicate MBG as an important factor in the
pathogenesis of this animal model which evidences many of the
characteristics of human PE [7]. We have also demonstrated that MBG
inhibits ﬁrst trimester cytotrophoblast (CTB) cell function [14–16].
Additionally, we have determined that MBG causes an increase in
vascular permeability [17], leading to hemoconcentration, which
occurs in human PE [18,19]. Recently, we reported the discovery of an
antagonist to MBG, resibufogenin (RBG), which has a similar chemical
structure to MBG [20–22]. When injected into “preeclamptic” rats
[20], RBG restored blood pressure to normotensive levels and
corrected the proteinuria.
When given early in pregnancy, RBG prevented the development
of hypertension, proteinuria, and intrauterine growth restriction
(IUGR) [22]. PE is associated with inﬂammatory changes in placental
tissues [23] and accumulation of circulating inﬂammatory cytokines
[24]. Placental stresses during pregnancy, notably hypoxia, ischemia
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important in the etiopathogenesis of PE [25–28].
The growth arrest and DNA damage-inducible (Gadd45) family of
genes are known to be associated with cell growth control, cell cycle
regulation, apoptotic cell death and the cellular response to DNA
damage [29–31]. Gadd45 is an important sensor of oxidative stress
and hypoxia [32,33]. Gadd45 proteins are signal transducers that
convert environmental and physiological stresses into various
cellular stress responses including inﬂammation, innate immunity
and autoimmune diseases [34–36]. The Gadd45 family genes encode
for small proteins (~18 kDa) that bind to and regulate the activity of
several downstream stress response proteins that ultimately
mediate activation of both p38 and Jnk stress response kinases
[33,37–40]. The Gadd45a stress sensor protein has been reported to
be an upstream modulator of pathophysiological changes observed
in human PE [41].
PE is a syndrome, not a single disease entity, which involves more
than one pathogenetic mechanism [9,10]. It has been postulated that a
signiﬁcant segment of the PE population is responding to the
secretion and elaboration of an excessive amount of MBG [42]. To
date, no study has focused on the role thatMBG plays in the regulation
of Gadd45a stress signaling in the pathogenesis of PE. In addition, the
effects of RBG on Gadd45a have not previously been studied. The
purpose of this study was to investigate the relationship/interactions
between MBG and Gadd45a stress signaling in the development of PE
in our rat model. We, therefore, examined the role of MBG in Gadd45a
stress signaling in this model of PE and determined whether RBG
antagonized the actions of MBG on Gadd45a. In addition, we
evaluated the effects of MBG on Gadd45a stress signaling in CTB
cells. We also determined the effect of RNAi-mediated inhibition of
Gadd45a expression on stress signaling in CTB cells.2. Materials and method
2.1. Animals
The surgical procedures and experimental protocol were con-
ducted at Texas A&M University Health Science Center/Scott & White
Hospital after approval by the Institutional Animal Care and Use
Committee. The facility is approved by the American Association for
Accreditation of Laboratory Animal Care in accordance with National
Institutes of Health guidelines.2.2. Animal preparation
Male (275–325 g) and female (200–250 g) Sprague–Dawley rats
were obtained from Charles River Laboratories (Wilmington, MA).
These animals were housed in the institutional animal facility and
allowed free access to standard rat chow (Lab Diet 5001 Laboratory
Rodent Diet) and tap water. They were maintained on a 12:12-hour
dark/light cycle. The room temperature and humidity were main-
tained at 25°±2 °C and 55% respectively. Four groups of animals were
studied: normal pregnant (NP, n=8); pregnant rats which received
weekly injections of desoxycorticosterone acetate and whose drink-
ing water was replaced with 0.9% saline (PDS, n=9); normal
pregnant rats injected with MBG (7.65 μg/kg/day, NPM, n=8); and
PDS rats injected daily with RBG (30 μg/kg/day, PDSR, n=8)
beginning once pregnancy had been established. Systolic blood
pressure was measured by the tail-cuff method (IITC Inc., LifeScience
Instruments, model 59). At 18–20 days of pregnancy, a 24-hour urine
was collected in the absence of food. Each animal was housed
separately in a metabolic cage. The animals were then sacriﬁced on
days 18–20 and blood samples were taken. Pups were counted and
examined.2.3. Urine and blood analyses
The 24-hour protein excretion was measured using the pyrogallol
red method (Total Protein Kit, Micro Pyrogallol Red Method, Sigma).
Creatinine was measured in the blood and urine on a Nova 16
Analyzer (Waltham, MA) and the creatinine clearance was calculated.
Hematocrit was measured using a StatSpin MP Multipurpose
Centrifuge (Norwood, MA).
2.4. Harvesting and preparation of placental tissue homogenates and
measurement of placental Gadd45a protein expression
Placental tissue was dissected, weighed and homogenized in a cold
buffer preparation (10 mM Tris–HCl pH=7.5, 0.3 M sucrose, 10 μM
apoptinin, 10 μM pepstatin, 10 μM leupeptin, and 1 mM PMSF). The
tissue homogenates were centrifuged (10,000×g for 60 min at 4 °C)
and the supernatant was collected and analyzed for protein
estimation [43]. The Gadd45a protein was measured by gel electro-
phoresis of the placental homogenate followed by detection with
immunoblotting (Western blotting) using anti-Gadd45a antibody as
described previously [41].
2.5. Caspase 3 and 8 activities in the placental tissue homogenates
Caspase 3 and 8 activities were determined using commercially
available assay kits (Calbiochem, La Jolla, CA) as described previously
[17]. The tissue homogenates were treated with the substrate
conjugate and incubated for 2 h at 37 °C. The DEVD substrate (caspase
3 assay) and IETD substrate (caspase 8 assay) provided in the assay
kits were labeled with a ﬂuorescent molecule, 7-amino-4-triﬂuor-
omethyl coumarin. The resulting ﬂuorescence was measured in a
ﬂuorescent plate reader, which measured excitation at 400 nm and
emission at 505 nm.
2.6. sFlt-1 concentration in the placental tissue homogenates
sFlt-1 was measured by commercially available kits (R & D
Systems) according to the instructions provided by the manufacturer
as described previously [25]. This assay employs the quantitative
sandwich enzyme immunoassay technique. A monoclonal antibody
speciﬁc for VEGF R1 (sFlt-1) was pre-coated onto a microplate.
Standards and samples were pipetted into the wells and any VEGF R1
present was bound by the immobilized antibody. After washing away
any unbound substances, an enzyme-linked polyclonal antibody
speciﬁc for VEGF R1 was added to the wells. Following a wash to
remove any unbound antibody-enzyme reagent, a substrate solution
was added to the wells. Color then developed in proportion to the
amount of VEGF R1 bound in the initial step. Color development was
then stopped and the intensity of the color was measured.
2.7. Cytotrophoblast cell culture
The human extravillous CTB cell line SGHPL-4 utilized in these
studies was derived from ﬁrst trimester extravillous tissue [44], and
was kindly provided by Dr. Guy Whitley (St. George's Hospital
Medical School, London, UK). These cells are well characterized and
share many characteristics with isolated primary cells, including the
expression of cytokeratin-7, HLA class I antigen, HLA-G, BC-1, CD9,
human chorionic gonadotropin and human placental lactogen [45–
48].
SGHPL-4 cells were cultured in Ham's F10 Nutrient Mix supple-
mentedwith 10% FBS, penicillin G (100 U/ml), streptomycin (100 mg/
ml) and 2 mM L-glutamine (Sigma). Cells were incubated at 37 °C, 5%
CO2, and 99% humidity (Fisher Scientiﬁc, Isotemp CO2 incubator). CTB
cells were seeded (7000 cells/well) onto 6-well plates in complete
medium and allowed to adhere overnight at 37 °C. Cells were then
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twice with 1× phosphate buffered saline (PBS). Four replicates were
subsequently treated with 10% FBS/Ham F12 containing DMSO
(vehicle) or 0.1, 1, 10 or 100 nM MBG. Cells were incubated for 24 h
with the respective treatments and were then collected for the
measurement of Gadd45a protein expression.
2.8. Gadd45a mRNA knockdown
CTB cells were sub-cultured to 30–50% conﬂuence 24 h before
transfection. Either 60 pmol Gadd45a RNAi or RNAi negative control
(Invitrogen) were added into the culture medium together with 10 μl
Lipofectamine RNAiMAX (Invitrogen). CTB cells were cultured with
the transfection reagents for 4–6 h. The transfection media was
replaced with normal media for 48 h prior to the indicated
treatments. The sense-strand sequence for two siRNAs is described
(a complementary oligonucleotide was synthesized) as follows:
GADD45a siRNAs 5′-AACGTCGACCCCGATAACGTG and 5′-
AACATCCTGCGCGTCAGCAAC. Chemically synthesized RNA oligonu-
cleotides were annealed, deprotected, and desalted as recommended
by the manufacturer.
2.9. Effect of MBG on cell cycle phase determination before and after
Gadd45a mRNA knockdown
Cell cycle progression was evaluated by Accuri's Cell Cycle Phase
Determination Kit (Cayman Chemical Company, Ann Arbor, MI). CTB
cells were treated with DMSO (vehicle), 0.1, 1, 10 or 100 nM MBG
before and after Gadd45amRNA knockdown. The cells were harvested
by trypsinization, and ﬁxed with 70% cold ethanol. Prior to ﬂow
cytometric analysis, the cells were washed and resuspended in PBS
containing 20 μg/ml of RNase A and 50 μg/ml propidium iodide. Cell
cycle analysis was performed on an Accuri C6 Flow Cytometer (Accuri
Cytometers, Inc., Ann Arbor, MI), and cellular DNA content was
analyzed with FCS Express software (De Novo Software, Los Angeles,
CA). Experiments were repeated at least four times.
2.10. Effect of MBG on apoptotic signaling of CTB cells before and after
Gadd45a mRNA knockdown
Apoptosis was evaluated by Accuri's Apoptotic Blebs Assay Kit
(Cayman Chemical Company, Ann Arbor, MI). The kit employs a
recombinant protein containing single-chain variable fragments fused
to the protein A, domain B fraction as an antibody for apoptotic blebs.
The protein A portion of this fusion protein is recognized and
visualized by ﬂuorescein-conjugated rabbit IgG. Propidium iodide is
included in the kit for detection of dead cells. CTB cells were treated
with DMSO (vehicle), 0.1, 1, 10 or 100 nM MBG before and after
Gadd45a mRNA knockdown. The apoptotic blebs assay was per-
formed on an Accuri C6 Flow Cytometer (Accuri Cytometers, Inc., Ann
Arbor, MI), and staining intensity was analyzed with FCS Express
software (De Novo Software, Los Angeles, CA). Experiments were
repeated at least four times.
2.11. Effect of MBG on p38 phosphorylation before and after Gadd45a
mRNA knockdown
The effect of MBG on p38 phosphorylation was evaluated by
immunoprecipitation and Western blot analysis. CTB cells were
treated with DMSO (vehicle) or 0.1, 1, 10 or 100 nM MBG for
60 min. After each treatment, total cellular protein was obtained in
lysis buffer containing 50 mM Tris at pH 7.4, 50 mM NaCl, 1% Triton X-
100, 0.1% SDS, 0.3 mM Na-orthovanadate, 50 mM NaF, 1 mM DDT,
10 μg/ml leupeptin and 5 μg/ml aprotinin. Protein concentrations
were determined by BCA reagent (Pierce). An equal amount of protein
in each sample was separated by 12% SDS/PAGE and transferred to anitrocellulose membrane. Membranes were blocked in 20 mM Tris
(pH 7.6), 250 mM NaCl containing 5% BSA and probed with mouse
anti-p38 polyclonal antibody (Santa Cruz). Following incubation with
peroxidase- or alkaline phosphatase-conjugated donkey anti-mouse
secondary antibody (Santa Cruz), proteins were visualized with a
chemiluminescence detection system (GE Healthcare). The intensity
of the bands was determined by scanning video densitometry using a
phospho-imager (Storm 860) and ImageQuant TL software version
2003.2 (GE Healthcare, Little Chalfont, Buckinghamshire, UK).2.12. Effect of MBG on sFlt-1 concentration before and after Gadd45a
mRNA knockdown
The concentration of sFlt-1 in CTB cell culture medium was
measured by commercially available kits (R & D Systems) according to
the instructions provided by themanufacturer as described previously
[25].2.13. Effect of MBG on the sFlt-1 receptor (VEGFR-1) before and after
Gadd45a mRNA knockdown
The effect of MBG on the sFlt-1 receptor was evaluated by
immunoprecipitation and Western blot analysis. CTB cells were
treated with DMSO (vehicle) or 0.1, 1, 10 or 100 nM MBG for 24 h.
The sFlt-1 receptor was measured by gel electrophoresis of the CTB
cell lysates followed by detection with immunoblotting (Western
blotting) using anti-VEGFR-1 antibody as described previously [41].2.14. Effect of MBG on 8-isoprostane (8-IP) concentration before and
after Gadd45a mRNA knockdown
CTB cells were treated with DMSO (vehicle), 0.1, 1, 10 or 100 nM
MBG before and after Gadd45a mRNA knockdown for 24 h. The levels
of 8-IP in the culture media of MBG-treated CTB cells were measured
by a commercially available ELISA kit (Cayman Chemical Company,
Ann Arbor, MI).2.15. Effect of MBG on IL-6 secretion before and after Gadd45a mRNA
knockdown
IL-6 concentrations in the serum-free media of CTB cells after
treatment with 0.1, 1.0, 10 or 100 nM MBG were determined by a
human IL-6 TiterZyme Enzyme Immunometric Assay (EIA) kit (Assay
Designs) [49,50]. The kit employs a monoclonal antibody to human IL-
6 immobilized on amicrotiter plate to bind human IL-6 in standards or
experimental samples. CTB cells were treated with 0.1, 1.0, 10 or
100 nM MBG in serum-free medium. After a 24-hour treatment,
media were collected from the ﬂasks seeded with CTB cells. Cells
treated with DMSO were used as controls. All of the samples were
collected from ﬂasks after treatment for determination of IL-6
concentration. After a short incubation, the excess sample or standard
was washed out and an antibody to human IL-6 was added. Following
a short incubation [14], the excess antibody was washed out and
donkey anti-rabbit IgG conjugated to HRP was added. After a short
incubation [14], the enzyme reaction was stopped and the color
generated was read at 450 nm.2.16. Statistical analysis
Data are presented as mean±SEM. Statistical comparisons for
multiple determinations were performed using a one-way ANOVA
analysis of variance with Tukey's post hoc test. A p value of b0.05 was
considered signiﬁcant.
Table 1
Blood pressure, urinary protein excretion, creatinine clearance, hematocrit values, and
number of pups in the four groups of animals.
Animal group NP
(n=8)
PDS
(n=9)
NPM
(n=8)
PDSR
(n=8)
Baseline BP
(mm Hg)
108±6 106±4 107±4 105±3
Final BP
(mm Hg)
91±5a,b 145±3a,c 133±7a,c 88±5a,b
Urinary protein
excretion
(mg/24 h)
2.5±0.7b 5.1±0.5c 4.7±0.5c 2.4±0.9b
Creatinine clearance
(ml/min)
0.82±0.28 1.04±0.45 1.14±0.37 0.96±0.28
Hematocrit 0.35±0.03b 0.39±0.03c 0.39±0.03c 0.34±0.03b
Number of pups 14.9±1.8b 10.8±1.3c 12.1±1.9c 14.6±1.2b
% Malformed pups 0%b 18%c 6%c 0%b
Values are mean±SE; n = number of rats. NP = normal pregnant animals; PDS =
pregnant animals receiving DOCA and saline; NPM = normal pregnant rats injected
with MBG; PDSR = PDS rats injected with RBG.
There were no differences in baseline BP between the groups.
a Statistically signiﬁcant difference between baseline BP and ﬁnal BP, pb0.05.
b NP and PDSR groups are different from PDS and NPM, pb0.05.
c PDS and NPM groups are different from NP and PDSR, pb0.05.
Fig. 2. Activation of caspase 3 and 8 activities in the placental tissues of the rat model of
PE. Caspase 3 and 8 activities were signiﬁcantly higher in the PDS and NPM groups
compared to the NP and PDSR animals (⁎pb0.002, n=5). The data are presented as the
mean±SEM.
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3.1. Blood pressure, urine and blood analyses
Data for blood pressure (BP) measurements, the urinary excretion
of protein, creatinine clearance, hematocrit levels and number of pups
are presented in Table 1. BP rose in the PDS and NPM animals
compared to NP and PDSR (pb0.05). BP in the NP animals fell over the
course of gestation, as was also the case in the PDSR rats. The PDS and
NPM animals showed a statistically signiﬁcant (pb0.05) increase in
protein excretion when compared with the NP and PDSR groups. The
mean hematocrit values for the PDS andNPM groupswere statistically
signiﬁcantly lower than those obtained in the NP and PDSR groupsFig. 1. Western blot analysis was performed to evaluate the expression of Gadd45a in
the placental tissues from the four groups of rats: normal pregnant (NP, n=8);
pregnant rats which received weekly injections of desoxycorticosterone acetate and
0.9% saline as their drinking water (PDS, n=9); normal pregnant rats injected with
MBG (NPM, n=8); and PDS rats injected with RBG (PDSR, n=8). The data were
expressed as the fold-change from NP utilizing densitometry. The Gadd45a protein
expression was signiﬁcantly higher in the PDS and NPM groups compared to the NP and
PDSR animals (⁎pb0.001, n=5). The data are presented as the mean±SEM.(pb0.05 in each case). Themean number of pups for the PDS and NPM
groups was signiﬁcantly lower than those obtained in the NP and
PDSR groups (pb0.05 in each case). There were no statistically
signiﬁcant differences in creatinine clearance between the groups.
These data reproduce the observations obtained in previous studies in
this animal model of preeclampsia [7,13]. Thus, the PDS and NPM
animals became hypertensive and demonstrated an increase in
protein excretion which exceeded that seen in the other two groups
of animals. As is the case in PE patients, the hematocrit values in our
PDS and NPM rats were higher than in the NP group (Table 1).
Likewise, the PDS animals and rats given MBG (NPM) demonstrated
hemoconcentration [51]. The lower number of pups in the PDS and
NPM groups compared to NP and PDSR rats reﬂect the fact that PDS
(“preeclamptic”) and NPM rats develop IUGR, while RBG prevents the
development of IUGR [22]. There were no malformed pups in the NP
and PDSR groups. The percentage of malformed pups for PDS and NPM
rats were 18% and 6% respectively (Table 1). This ﬁnding indicates that
RBG prevented the development of IUGR.3.2. Gadd45a protein expression in the placental tissues
Western blot analysis was performed to evaluate the expression of
Gadd45a in the placental tissues from the four groups of rats. Gadd45a
protein expression was signiﬁcantly higher in the PDS and NPM
groups compared to the NP and PDSR animals (Fig. 1). The stressFig. 3. sFlt-1 concentrations in the placental tissues from the four groups of rats were
assayed utilizing a commercially available kit. sFlt-1 concentrations are expressed as
ng/g tissue. SFlt-1 was signiﬁcantly higher in the PDS and NPM groups compared to the
NP and PDSR animals (⁎pb0.05, n=5). The data are presented as the mean±SEM.
Fig. 4. Western blot analysis was performed to evaluate the expression of VEGFR-1 in
the placental tissues from the four groups of rats. The data are expressed as the fold-
change over NP utilizing densitometry. Gadd45a protein expression was signiﬁcantly
higher in the PDS and NPM groups compared to the NP and PDSR animals (⁎pb0.001,
n=5). The data are presented as the mean±SEM.
53M.N. Uddin et al. / Biochimica et Biophysica Acta 1812 (2011) 49–58sensor protein Gadd45a was upregulated in the placental tissues of
our ratmodel and in the normal pregnant rats injected withMBG. RBG
prevented this alteration in the placental tissues of the PDSR animals.Fig. 5. Gadd45a protein was activated in the MBG-treated CTB cells. (A) The Western
blot data were analyzed utilizing densitometry. Gadd45a protein expression was
signiﬁcantly increased in 1, 10 and 100 nM MBG-treated cells when compared to the
DMSO (vehicle)-treated cells (⁎pb0.001, n=5, 8 replicates each). The 0.1 nM MBG
treatment had no effect. (B) The RNAi-mediated inhibition of Gadd45a expression.
Fig. 6. (A) Cell cycle progression in CTB cells was arrested by MBG. The MBG-induced
effect on cell cycle arrest was determined by ﬂuorescence-activated cell sorting (FACS)
analysis. G0/G1 is the resting/early interphase, S represents synthetic (mid-interphase)
and G2/M is the late interphase/mitotic phase. MBG (1, 10 or 100 nM) signiﬁcantly
arrested progression of the cell cycle compared to DMSO (vehicle)-treated cells,
whereas 0.1 nMMBG had no effect. There was a signiﬁcantly higher percentage (~80%)
of cells in the G0/G1 phase in the MBG 1, 10 and 100 nM treated cells compared to basal
and to 0.1 nM treated cells (~55%) (⁎pb0.05, n=5, 8 replicates each). (B) The MBG-
induced cell cycle arrest was attenuated by siRNA knockdown of Gadd45a. Results are
presented as the mean±SEM (n=5, 8 replicates each).3.3. Caspase 3 and 8 activities in the placental tissues
Caspases are the molecular instigators of apoptosis. Caspase 3 and
8 activities were signiﬁcantly higher in the PDS and NPM groups
compared to the NP and PDSR animals (Fig. 2). Apoptotic signaling
was observed in the placental tissues of our rat model and in the NPM
rats. This signaling was prevented in the placental tissues of RBG-
injected PDS animals.3.4. sFlt-1 concentration in placental tissues
sFlt-1 was signiﬁcantly higher in the PDS and NPM groups
compared to the NP and PDSR animals (Fig. 3). sFlt-1, a downstream
stress response protein of Gadd45a was upregulated in our rat model
and in the NPM rats. This alteration was attenuated in the placental
tissues of the PDSR rats.3.5. sFlt-1 (VEGFR-1) receptor expression in placental tissues
VEGFR-1 was signiﬁcantly upregulated in our rat model of PE and
normal pregnant rats injected with MBG. This alteration was
attenuated in the placental tissues of the RBG-injected PDS rats
(Fig. 4).
Fig. 7. (A) MBG≥1 nM signiﬁcantly induced apoptotic signaling compared to DMSO
(vehicle)-treated cells, whereas 0.1 nM MBG had no effect. There was a signiﬁcantly
lower percentage (~60%) of healthy cells in the MBG≥1 nM treated cells compared to
basal and to 0.1 nM treated cells (~90%). (B) The MBG-induced apoptotic signaling in
CTB cells was abolished by siRNA knockdown of Gadd45a. Results are presented as the
mean±SEM (n=5, 8 replicates each).
Fig. 8. (A) Increased p38 phosphorylation byMBG. CTB cells were treated with 0.1, 1, 10
or 100 nM MBG and p38 phosphorylation was measured by Western blotting. p38
phosphorylation was increased signiﬁcantly in ≥1 nM MBG-treated cells when
compared to DMSO (vehicle)-treated cells (⁎pb0.003, n=5). The results are expressed
as the ratio of phosphorylated-p38 (p-p38) to the total-p38 (t-p38) in MBG-treated
and DMSO-treated cells and to 0.1 nM treated cells. (B) The RNAi-mediated inhibition
of Gadd45a expression prevented the MBG-induced upregulation of p38 phosphory-
lation. Results are presented as the mean±SEM.
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Gadd45a protein expression was signiﬁcantly increased in 1, 10 and
100 nMMBG-treated CTB cells when compared to the DMSO (vehicle)-
treated cells. The 0.1 nMMBG treatment had no effect (Fig. 5A).
3.7. Gadd45a protein knockdown
The RNAi-mediated inhibition of Gadd45a expression completely
knockdown the Gadd45a protein in CTB cells (Fig. 5B).
3.8. Effect of MBG on cell cycle progression
Gadd45a is an upstream activator of cell cycle arrest. MBG (1, 10 or
100 nM) signiﬁcantly arrested progression of the cell cycle compared
to DMSO (vehicle)-treated cells, whereas 0.1 nM MBG had no effect
(Fig. 6A). There was a signiﬁcantly higher percentage (~80%) of cells
in the G0/G1 phase in the MBG 1, 10 and 100 nM treated cells
compared to basal and to 0.1 nM treated cells (~55%) (pb0.05). The
effect of MBG on cell cycle progression in CTB cells was prevented by
Gadd45a knockdown (Fig. 6B).
3.9. Effect of MBG on apoptotic signaling
Apoptosis was evaluated by FACS analysis. MBG (1, 10 or 100 nM)
signiﬁcantly induced apoptotic signaling compared to DMSO (vehicle)-
treated cells, whereas 0.1 nM MBG had no effect (pb0.05) (Fig. 7A).
Therewas a signiﬁcantly lower percentage (~60%) of healthy cells in the
MBG 1, 10 and 100 nM treated cells compared to basal and to 0.1 nM
treated cells (~90%) (Fig. 7A) (pb0.05). The effect of MBG on the
apoptotic signaling in CTB cells was prevented by Gadd45a knockdown
(Fig. 7B).3.10. Effect of MBG on p38 phosphorylation in CTB cells
MBG (1, 10 and 100 nM) caused a signiﬁcant increase in the ratio
of phosphorylated p38 to total p38 in CTB cells compared to basal and
to 0.1 nM treated cells (Fig. 8A) (pb0.05). MBG had no effect on total
p38 expression demonstrating that the changes in the ratio were due
to increased phosphorylation. The RNAi-mediated inhibition of
Gadd45a expression abolished the MBG-induced upregulation of
p38 phosphorylation (Fig. 8B).
3.11. Effect of MBG on sFlt-1 secretion in CTB cells
The application of MBG≥1 nM signiﬁcantly increased the secre-
tion of sFlt-1 in the culture medium of CTB cells (Fig. 9A). The RNAi-
mediated inhibition of Gadd45a prevented this effect (Fig. 9B).
Fig. 9. (A) MBG induced sFlt-1 secretion. CTB cells were treated with 0.1, 1, 10 or
100 nM MBG and sFlt-1 concentrations were measured in the cell culture media by a
commercially available EIA kit. sFlt-1 concentration was increased signiﬁcantly
in ≥1 nM MBG-treated cells when compared to DMSO (vehicle)-treated cells and to
0.1 nM treated cells (⁎pb0.05, n=5, 8 replicates each). (B) The RNAi-mediated
inhibition of Gadd45a expression prevented the MBG-induced upregulation of sFlt-1.
Results are presented as the mean±SEM (n=5, 8 replicates each). Fig. 10. (A) Effect of MBG on VEGFR-1 expression. CTB cells were treated with 0.1, 1, 10
or 100 nM MBG and VEGFR-1 was measured by Western blotting. VEGFR-1 expression
was increased signiﬁcantly in ≥1 nM MBG-treated cells when compared to DMSO
(vehicle)-treated cells and to 0.1 nM treated cells (⁎pb0.003, n=5). (B) The RNAi-
mediated inhibition of Gadd45a expression prevented the MBG-induced upregulation
of VEGFR-1 expression. Results are presented as the mean±SEM.
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MBG (1, 10 and 100 nM) caused a signiﬁcant increase in the
VEGFR-1 expression in CTB cells compared to basal and to 0.1 nM
treated cells (Fig. 10A) (pb0.05). The RNAi-mediated inhibition of
Gadd45a expression abolished the MBG-induced upregulation of
VEGFR-1 in CTB cells (Fig. 10B).
3.13. Effect of MBG on 8-IP secretion in CTB cells
The administration of MBG≥1 nM signiﬁcantly increased the
secretion of 8-isoprostane in CTB cells (Fig. 11A). The effect was
abolished in the Gadd45a knockdown CTB cells (Fig. 11B).
3.14. Effect of MBG on IL-6 secretion in CTB cells
The administration of 1, 10 and 100 nMMBG induced the secretion
of IL-6 in the culture medium of CTB cells compared to DMSO-treated
and to 0.1 nM treated cells (Fig. 12A). The RNAi-mediated inhibition
of Gadd45a expression abolished this effect in CTB cells (Fig. 12B).
4. Discussion
We have proposed that excessive volume expansion in pregnancy
[41] serves as the initial stimulus for the increased levels of circulating
MBG very early in pregnancy [7,42]. The addition of MBG to CTBs in cellculture causes cytotrophoblast dysfunction [14–16]. Assuming that this
situation also obtains in vivo, defective placentation would supervene.
The syndrome of PE is thought to result from inadequate “placentation”
related to a failure of theCTBcells to adequately remodel thevasculature
of the uterus in a signiﬁcant segment of the PE population [52]. This
results in hypoperfusion of the maternal–fetal unit, and is thought to
result in oxidative stress and endothelial dysfunction, which are
responsible for the development of the syndrome [53]. The resultant
hypoxia and ischemiawould lead to a continued elevation inMBG levels
in preeclamptic patients. Placental stresses during PE cause the
induction of Gadd45a and the activation of its downstream effector
p38, which in turn induces the secretion of sFlt-1 [41]. Therefore, we
investigated the consequences of MBG-induced Gadd45a stress signal-
ing inour ratmodel of PE. This studyprovidesnovel data suggesting that
Gadd45a expression, apoptotic signaling, and sFlt-1 receptor expression
are upregulated in the placental tissues of our rat model (Figs. 1–4).
MBGwas found to be involved in the causation of these alterations, and
RBG prevented these changes. The administration of MBG to pregnant
rats reproduces the syndrome of PE, which includes hypertension and
proteinuria [20,54].Wehave reported thatRBG corrects hypertension in
the rat model of PE [20] and, when administered early in pregnancy,
completely prevents all of the manifestations of the PE syndrome [22].
Fig. 11. (A) Effect of MBG on 8-IP secretion. CTB cells were treated with DMSO, 0.1, 1, 10
or 100 nM MBG and 8-IP was measured in the cell media by EIA. MBG≥1 nM
signiﬁcantly increased the secretion of 8-IP compared to DMSO (vehicle)-treated cells
and to 0.1 nM treated cells (⁎pb0.05, n=5, 8 replicates each). (B) The MBG-induced
upregulation of 8-IP secretion by CTB cells was eliminated by siRNA knockdown of
Gadd45a. Results are presented as the mean±SEM (n=5, 8 replicates each).
Fig. 12. (A) Effect of MBG on IL-6 secretion. CTB cells were treated with DMSO, 0.1, 1, 10
or 100 nM MBG. IL-6 was measured by a commercially available EIA kit. MBG
concentrations of ≥1 nM signiﬁcantly increased the secretion of 8-IP compared to
DMSO (vehicle)-treated cells and to 0.1 nM treated cells (⁎pb0.05, n=5, 8 replicates
each). (B) The RNAi-mediated inhibition of Gadd45a expression prevented the MBG-
induced secretion of IL-6 by the CTB cells. Results are presented as the mean±SEM
(n=5, 8 replicates each).
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Increased apoptosis has been observed in extravillous trophoblast cells
of placentas from pregnancies complicated by PE and IUGR [57,58].
Important progress in our understanding of the pathogenesis of PE
resulted from the ﬁnding of an increase in circulating antiangiogenic
factors such as sFlt-1 [25], which is barely detectable in normal
pregnancies. In an animal model, the administration of sFlt-1 elicited
many of the typical pathologic changes associated with preeclamptic
pregnancies [25]. Xiong et al., showed that induction of Gadd45a
expression was required upstream of hypoxia-mediated sFlt-1 induc-
tion [41]. Our data are in agreement with the latter study. Furthermore,
the data in this communication indicate the involvement of MBG in the
Gadd45a stress signaling cascade. Moreover, we have demonstrated
that RBG prevents Gadd45a stress signaling. Recently, it has been
suggested that autoantibodies from women with PE induce sFlt-1
production via angiotensin receptor activation and calcineurin signaling
[59].Most recently, studies in the authors' laboratory demonstrated that
the administration ofMBGproducedanupregulation of theAT1 receptor
in the placental tissue of this rat model of PE [60]. The administration of
RBG, an antagonist ofMBG, prevented these changes in the AT1 receptor
[60]. Whether Gadd45a interferes with the MBG-induced AT1 receptor-
signaling cascade remains to be investigated.
To determine the cellular mechanisms of Gadd45 signaling, we
examined the effect of MBG on the Gadd45a stress signaling cascade
in CTB cells. We found that Gadd45a expression was upregulated in
MBG-treated CTB cells (Fig. 5). The MGB-induced cell cycle arrest in
CTB cells was prevented by the siRNA knockdown of Gadd45a (Fig. 6Aand B). Gadd45a is an upstream activator of cell cycle arrest. Inhibiting
endogenous expression of Gadd45 genes in human cells by antisense
Gadd45 constructs was found to impair cell cycle arrest following
exposure to UV radiation [61,62]. In addition, microinjection of a
Gadd45a expression vector into primary human ﬁbroblasts arrested
the cell cycle [62]. Similarly, in the studies presented in this
communication, MBG-induced apoptotic signaling in CTB cells was
abolished by the knockdown of Gadd45a (Fig. 7A and B). Ample
evidence exists that Gadd45 proteins have a pro-apoptotic function
[36,63,64]. An ectopic expression of Gadd45 proteins was shown to
induce apoptosis in HeLa cells [36] as well as enhance stress-mediated
apoptosis in both M1 leukemia and H1299 lung carcinoma cells [63].
This induction of apoptosis was shown to be dependent upon the
interaction of Gadd45 proteins with MEKK4, an upstream activator of
the stress-induced p38/Jnk kinases [36]. Furthermore, Gadd45a has
been implicated in apoptosis of UV-irradiated keratinocytes [64].
As we have previously reported [14], MBG signiﬁcantly increased
the phosphorylation of p38 in CTB cells. The RNAi-mediated inhibition
of Gadd45a expression abolished the MBG-induced upregulation of
p38 (Fig. 8A and B). The stimulated Jnk and p38 pathways are known
to regulate cell proliferation, invasion, survival, migration, growth
arrest and apoptosis [65,66].
The knockdown of Gadd45a prevented the MBG-induced induc-
tion of sFlt-1 secretion, sFlt-1 receptor expression, 8-IP and IL-6
secretion in CTB cells (Figs. 9A and B; 10A and B; 11A and B; 12A and
B). Xiong et al., demonstrated that the induction of Gadd45 expression
and its activation of p38 were required upstream of sFlt-1 induction
[41]. In a previous study, we have shown that p38 inhibition
prevented the secretion of IL-6 by CTB cells in response to MBG [14].
Fig. 13.Working model for MBG-induced Gadd45a signaling in the pathogenesis of PE. Excessive volume expansion in pregnancy causes an increase in the circulating levels of MBG.
MBG causes the induction of Gadd45a stress signaling which in turn activates p38 phosphorylation, IL-6 secretion, and apoptotic signaling and suppresses cell cycle progression.
Consequently, this stress signaling accelerates the secretion of sFlt-1. These events result in oxidative stress and, concomitantly, endothelial dysfunction. The administration of RBG, a
speciﬁc antagonist of MBG, early in pregnancy, prevents the development of this syndrome and its phenotypic characteristics. The RNAi-mediated inhibition of Gadd45a expression
prevented the MBG-induced CTB cell stress signaling.
57M.N. Uddin et al. / Biochimica et Biophysica Acta 1812 (2011) 49–58The inﬂammatory cytokine IL-6 has been reported to be
increased in the serum of severe cases of PE [67], which, in turn,
also causes increased secretion of sFlt-1 mediated via Gadd45a-p38
signaling. It has been suggested that Gadd45a-p38 signaling may
also function to promote the development of a preeclamptic state by
increasing the levels of IL-6 [41]. Thus, strategies to diminish the
presence of this cytokine in the inﬂammatory cascade, or to combat
the production of other cytokines (e.g. with IL-10) or with anti-
inﬂammatory agents [68] may represent another avenue in the
approach to the treatment of this disorder. The action of MBG may
occur upstream of the Gadd45-p38-IL6-mediated stress signaling in
the pathogenesis of PE. It seems likely that intervention in the
Gadd45a stress signaling pathway might represent a preventive or
therapeutic stratagem in PE. Further work using more elaborate in
vitro (i.e., placental explants) and in vivo (i.e., Gadd45a null mice)
models will be needed to understand the role of Gadd45a stress
signaling in the etiology of PE.
Fig. 13 depicts a proposed model of the involvement of elevated
levels of MBG in Gadd45a-mediated stress signaling in PE. An increase
in the circulating level of MBG is suspected to be related to initial
excessive volume expansion early in pregnancy [42]. In this
postulated sequence of events, MBG causes the induction of
Gadd45a stress signaling, which in turn activates p38 and apoptotic
signaling [14]. Consequently, secretion of sFlt-1 is induced [25]. All of
these abnormalities culminate in the production of endothelial cell
dysfunction [69] and oxidative stress [12]. These baleful actions of
MBG can be prevented by the in vivo administration of RBG. This
action of MBG, which is mediated by p38, and involves the activation
of apoptosis, can be prevented in vitro by the addition of a p38
inhibitor [14]. The data of the current study as well as previous reportssuggest that the employment of Gadd45a or p38 inhibition may
represent an important therapeutic strategy in PE.Acknowledgements
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